boehringer ingelheim glp-1 ADA: Tolerability questions linger for Boehringer's obesity drug Boehringer's GLP-1 dual agonist survodutide

I believe the side effects profile for management of diabetes is not the same as for management of obesity.

Results can support a more personalized conversation between patient and provider about whether a GLP-1 monotherapy, dual-peptide strategy (e.g., GLP-Squared), or microdose protocol aligns better with identified pathway predispositions

An alternative approach aiming to maximize the efficacy of GLP-1 involves the delivery of nuclear receptor agonists to specific tissues characterized by the expression of GLP-1R

doi: 10.1080/00207454.2021.1924707 [DOI] [PubMed] [Google Scholar] 86

Obesity is a complex condition extending beyond metabolic complications and has been shown to lead to neurologic disorders